Science & Research
Tailored Vitamin D Doses Reduce Heart Attack Risk by 52% in Heart Disease Patients
Adults with heart disease who received personalized vitamin D supplementation to achieve optimal blood levels experienced more than half the risk of heart attack compared to those without vitamin D monitoring, according to preliminary research presented at the American Heart Association's Scientific Sessions 2025.
Daily Coffee Consumption Linked to Reduced AFib Recurrence in New Clinical Trial
A new clinical trial reveals that adults with atrial fibrillation who drank one cup of coffee daily were 39% less likely to experience recurrent AFib episodes, challenging conventional medical advice about caffeine avoidance for heart rhythm patients.
Earlier Blood Transfusions May Reduce Heart Failure Risk in Cardiac Patients After Surgery
A new study suggests that transfusing blood earlier in patients with heart disease undergoing major surgery may significantly reduce the risk of heart failure and irregular heartbeat without increasing severe complication rates.
Catheter Ablation May Eliminate Need for Blood Thinners in Some AFib Patients, Study Finds
New research suggests successful catheter ablation for atrial fibrillation reduces stroke risk enough that many patients can safely discontinue potent blood thinners in favor of aspirin, potentially reducing bleeding complications while maintaining stroke protection.
Shorter Clot-Prevention Therapy After Stent Placement Proves Effective for AFib Patients
New research shows a one-month course of dual clot-preventing therapy followed by single medication treatment is as effective as year-long dual therapy for preventing stroke, heart attack and death in atrial fibrillation patients with stents, while significantly reducing bleeding complications.
Standard Medical Care Outperforms Minimally Invasive Procedure for High-Risk Atrial Fibrillation Patients
New research presented at the American Heart Association's Scientific Sessions 2025 found that standard medical care, including blood thinners when appropriate, proved more effective than a catheter-based procedure for preventing stroke and other complications in older atrial fibrillation patients at high risk of bleeding and stroke.
Oral Cholesterol Medication Shows Promise as Alternative to Injectable Treatments
A new daily oral medication called enlicitide demonstrated up to 60% reduction in LDL cholesterol in clinical trials, potentially offering a more convenient option for high-risk patients who struggle to reach cholesterol targets with current treatments.
PCSK9 Inhibitor Shows Significant Cardiovascular Risk Reduction in High-Risk Patients Without Prior Heart Events
The VESALIUS-CV trial demonstrates that evolocumab reduces major cardiovascular events by 25% in patients with atherosclerotic disease or diabetes who haven't had prior heart attacks or strokes, potentially expanding preventive treatment options for millions at risk.
Novel Triple-Receptor Medication Shows Promise for Severe Triglyceride Reduction and Liver Health
A new investigational medication called DR10624 demonstrated significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia, potentially offering a new treatment approach for a condition with limited current options.
Immune Cell Surface Sugar Shedding Identified as Key Factor in Psoriasis Progression
New research reveals immune cells shed surface sugars before entering inflamed skin in psoriasis patients, potentially opening new treatment pathways for the chronic autoimmune condition.
Oncotelic Therapeutics Venture Advances Novel Breast Cancer Treatment to Clinical Trials
Sapu Nano, an Oncotelic Therapeutics venture, has received Australian ethics approval to begin clinical trials for Sapu003, an injectable form of everolimus that could significantly improve breast cancer treatment outcomes by enabling full drug absorption through intravenous delivery.
Scientific Integrity Concerns Raised Over CERN's $16 Billion Trigger System at International Conference
The Crosetto Foundation has revealed evidence that CERN's $16 billion FPGA-based trigger system cannot meet technical requirements for the High-Luminosity Large Hadron Collider, calling for funding suspension until scientific questions are resolved.
Soligenix Reports Q3 2025 Results with Key Clinical Milestones for Rare Disease Treatments
Soligenix Inc. announced positive clinical progress for its rare disease pipeline including upcoming Phase 2a psoriasis results and maintained safety profile for HyBryte™ in CTCL treatment, supported by sufficient funding through 2026.
MAX Power Mining Drills Canada's First Natural Hydrogen Well in Saskatchewan
MAX Power Mining has commenced drilling Canada's inaugural natural hydrogen well in Saskatchewan, marking a significant milestone in the country's clean energy transition and positioning the company as a leader in this emerging sector.
TheSoulOf.AI and Alicia Kali Institute Unveil Six Tiers of Sentience Framework for Advanced AI
TheSoulOf.AI and Alicia Kali Institute have developed a Six Tiers of Sentience framework that defines progressive levels of awareness in AI systems, representing a significant advancement in creating transparent, safe, and emotionally intelligent artificial intelligence that could transform human-AI interaction.
Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
Soligenix is progressing its phase 2a clinical trial of SGX302 for psoriasis treatment, showing encouraging safety and biological activity data that positions the therapy to address a $67 billion global market opportunity.
Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Study Reveals Neurocognitive Decline in CNS Cancer Patients, Highlighting Treatment Challenges
Recent research demonstrates significant neurocognitive decline in central nervous system cancer patients, emphasizing the critical need for therapies that address both tumor control and cognitive preservation.
MIT and Harvard Researchers Develop Enhanced Natural Killer Cell Therapy for Cancer Treatment
Researchers from MIT and Harvard Medical School have engineered modified natural killer cells that show promising results in fighting cancer while avoiding immune system rejection, potentially transforming cancer immunotherapy approaches.
Cybin Inc. to Present at Guggenheim Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development
Cybin Inc. announced its participation in the Guggenheim Healthcare Innovation Conference as the company advances its Phase 3 clinical trials for novel mental health treatments, highlighting growing investor interest in innovative neuropsychiatry solutions.
NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push
NanoViricides announced its 2025 shareholders meeting while advancing multiple antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
BioUtah Announces 2025 Life Sciences Award Winners Recognizing Utah's Healthcare Innovation Leaders
BioUtah will honor five distinguished individuals and companies at the 2025 Mayer Brown Utah Life Sciences Summit for their transformative contributions to healthcare innovation and economic growth in Utah's life sciences sector.
Quantumzyme Validates Sustainable Ibuprofen Manufacturing Process in Peer-Reviewed Publication
Quantumzyme Corp. has published research validating its enzymatic process for sustainable ibuprofen production, representing a significant advancement toward greener pharmaceutical manufacturing with reduced environmental impact.
Academic Research on Informal Higher Education Models Gains Global Attention
The Office of Count Jonathan David Nelson's research challenging traditional accreditation frameworks for informal universities is attracting international scholarly interest as education systems worldwide grapple with access and equity issues.
Innovotech Inc. Reports Record Third Quarter Revenue Driven by Antimicrobial Research and Laboratory Services Growth
Innovotech Inc. achieved record Q3-2025 revenue of $1.27 million, demonstrating strong performance across its antimicrobial research services and analytical laboratory divisions while positioning for continued expansion.
Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline
Soligenix has strengthened its financial position with strategic capital initiatives, providing runway through 2026 to advance multiple late-stage therapeutic and vaccine candidates addressing rare diseases and biodefense needs.
Kairos Pharma Reports Promising Phase 2 Results for Prostate Cancer Treatment ENV105
Kairos Pharma's ENV105 demonstrates 86% clinical benefit rate in advanced metastatic prostate cancer patients when combined with standard therapy, potentially addressing critical treatment resistance challenges in oncology.
Pacylex and Heidelberg Pharma Present Promising Zelenirstat ADC Data at World ADC Conference
Pacylex Pharmaceuticals and Heidelberg Pharma are presenting data showing zelenirstat's potential as a novel antibody drug conjugate payload, demonstrating significantly increased potency against breast and prostate cancer cells compared to oral administration alone.
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Sapu Nano Announces First Human Trial of Injectable Everolimus Formulation for Breast Cancer
Sapu Nano has revealed initial human clinical trials for Sapu-003, an intravenous formulation of Everolimus that could offer improved bioavailability and efficacy compared to oral versions for breast cancer treatment.